Duodenal carcinoid with carcinoid syndrome

Naalla, Ravikiran; Konchada, Kamesh; Kannappan, Odaiyappan; Ramachandra, Lingadakai

doi:10.1136/bcr-2013-202159

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar case of duodenal carcinoid was reported by Nalla et al (2014) [13] from India. Our case was probably the first one to be reported from Bangladesh.…”

Section: Discussionsupporting

confidence: 83%

“…Serum chromogranin and urinary 5-HIAA can be used for follow up. Other methods like EUS, CT, MRI & somatostatin receptor scintigraphy (SRS) can also be used for this purpose [13].…”

Section: Discussionmentioning

confidence: 99%

“…These agents are effective in controlling the symptoms in patients with carcinoid syndrome. [13]. Surgical resection has been shown to be effective in reducing symptoms of carcinoid syndrome and in improving survival [1].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Carcinoid Syndrome in a Patient with Duodenal Carcinoid Tumor

Saqeb¹,

Sharmeen²,

Hafiz³

2021

CRJ

View full text Add to dashboard Cite

Duodenal carcinoid tumors accounts for 5% of all Gastrointestinal Neuroendocrine Tumors (GI-NETs). Only 4% of all duodenal carcinoid tumors present with a full-blown carcinoid syndrome. We report a case of duodenal carcinoid tumor presenting as carcinoid syndrome in a 58 year old man, who presented with upper abdominal discomfort, diarrhoea, hot flushes and occasional wheezing. Histopathology following endoscopic resection of the tumor and 24 hour urinary 5-Hydroxyindolacetic acid (5-HIAA) confirmed the diagnosis. Duodenal carcinoid tumors are one of the rarest tumors of gastrointestinal tract and their association with a typical carcinoid syndrome is not that common. A high level of suspicion is required for an early diagnosis. With proper resection (endoscopic or surgical) of a localized tumor, recurrence and progression of the disease can be halted. Symptoms of carcinoid syndrome should be controlled by antidiarrheal agents, inhaled βadrenergic agonist bronchodilators and somatostatin analogs (octreotide, lanreotide). Patients should be advised to avoid stress and conditions or substances that precipitate these symptoms. Dietary supplementation with nicotinamide can help in this regard. Patients with hepatic metastases are treated with synthetic analogues of somatostatin (octreotide, lanreotide). Systemic chemotherapy is not recommended in metastatic disease by the current guidelines. Patients should be followed up by monitoring serum chromogranin and urinary 5-HIAA. EUS, CT, MRI & somatostatin receptor scintigraphy can also be used for following up the patients.

show abstract

“…A similar case of duodenal carcinoid was reported by Nalla et al (2014) [13] from India. Our case was probably the first one to be reported from Bangladesh.…”

Section: Discussionsupporting

confidence: 83%

“…Serum chromogranin and urinary 5-HIAA can be used for follow up. Other methods like EUS, CT, MRI & somatostatin receptor scintigraphy (SRS) can also be used for this purpose [13].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Carcinoid Syndrome in a Patient with Duodenal Carcinoid Tumor

Saqeb¹,

Sharmeen²,

Hafiz³

2021

CRJ

View full text Add to dashboard Cite

show abstract

“…When feasible, endoscopic resection is supported by the 2016 NCCN guidelines[ 25 ]. Surgical resection has been recommended for duodenal NETs larger than 1 cm, especially when there is imaging evidence of lymph node involvement or higher mitotic index[ 34 ]. Once again, careful examination of the lesion by endoscopic ultrasound is important to determine size and depth of invasion, as well as lymph node metastases.…”

Section: Small Intestinementioning

confidence: 99%

Evolving role of the endoscopist in management of gastrointestinal neuroendocrine tumors

Yazıcı

Boulay

2017

WJG

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are uncommon gastrointestinal neoplasms but have been increasingly recognized over the past few decades. Luminal NETs originate from the submucosa of the gastrointestinal tract and careful endoscopic exam is a key for accurate diagnosis. Despite their reputation as indolent tumors with a good prognosis, some NETs may have aggressive features with associated poor long-term survival. Management of NETs requires full understanding of tumor size, depth of invasion, local lymphadenopathy status, and location within the gastrointestinal tract. Staging with endoscopic ultrasound or cross-sectional imaging is important for determining whether endoscopic treatment is feasible. In general, small superficial NETs can be managed by endoscopic mucosal resection and endoscopic submucosal dissection (ESD). In contrast, NETs larger than 2 cm are almost universally treated with surgical resection with lymphadenectomy. For those tumors between 11-20 mm in size, careful evaluation can identify which NETs may be managed with endoscopic resection. The increasing adoption of ESD may improve the results of endoscopic resection for luminal NETs. However, enthusiasm for endoscopic resection must be tempered with respect for the more definitive curative results afforded by surgical treatment with more advanced lesions.

show abstract